$LEGN News

Morgan Stanley Maintains Overweight on Legend Biotech, Raises Price Target to $49

TD Cowen Maintains Hold on Legend Biotech, Lowers Price Target to $24

Oppenheimer Downgrades Legend Biotech to Perform, Lowers Price Target to $40

RBC Capital Maintains Outperform on Legend Biotech, Lowers Price Target to $58

Barclays Maintains Overweight on Legend Biotech, Lowers Price Target to $78

Legend's Pipeline Is Starting To Matter

Legend Biotech Corporation 2026 Q2 - Results - Earnings Call Presentation

Legend Biotech Corporation (LEGN) Q2 2026 Earnings Call Transcript

Legend Biotech Q2 Adj. EPS $0.16 Beats $0.07 Estimate, Sales $387.500M Beat $355.772M Estimate

HC Wainwright & Co. Reiterates Buy on Legend Biotech, Maintains $65 Price Target

RBC Capital Maintains Outperform on Legend Biotech, Lowers Price Target to $59

Legend Biotech CEO Ying Huang Steps Down, Alan Bash Named Interim CEO

UBS Downgrades Legend Biotech to Neutral, Lowers Price Target to $28

JP Morgan Reinstates Neutral on Legend Biotech, Announces $35 Price Target

RBC Capital Maintains Outperform on Legend Biotech, Lowers Price Target to $63

Legend Biotech Commences $225M Offering Of Its American Depositary Shares

Reported Sunday, Legend Biotech's LB2501 In Vivo CD19/CD20 Dual-Targeting CAR-T Achieves 100% ORR And 83.3% CR Rate At Dose Level 2 In Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

UBS Maintains Buy on Legend Biotech, Raises Price Target to $49

Legend Biotech Jumps 42% On New Data -- Here's What Comes Next

HC Wainwright & Co. Maintains Buy on Legend Biotech, Raises Price Target to $65